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Goals:
The goal of this article is to provide a review of
available evidence for safe prescribing in older
adults and recommend medication therapies
based on anticipated
pharmacokinetic/physiologic changes in this
population.
Learning Objectives:
Upon completion of this article, the learner
should be able to:
1. Describe the physiologic and
pharmacokinetic changes of aging that
impact drug therapy and dosing.
2. Identify the medications or medication
classes included on the Beer’s Criteria
3. Recognize the medications on the
STOPP/START lists.
4. Compare and contrast different
methods of identifying potentially
inappropriate medications for the
elderly patients
5. Discuss the pharmacist’s role in and
approach to medication management
for the older persons.
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Definitions
1. Older adults are persons over the age
of 65 years. Also referred to as elderly
or geriatric.
2. Potentially inappropriate medications
(PIMs) are drugs that have unfavorable
benefit-to-risk ratio when safer or
equally effective alternatives are
available.1-3
3. Implicit criteria use the entire clinical
picture when assessing the
appropriateness of a medication. The
benefit of implicit criteria is the
specificity for each patient. However,
clinical judgment is needed and this can
vary between practitioners. Implicit
criteria are typically not used in clinical
trials due to the low inter-rater
reliability.1,2
4. Explicit criteria are created based on
specific drugs or drug-related triggers.
Unlike implicit criteria, explicit criteria
can be used easily in clinical trials
because of the high degree of interrater reliability. Most of the tools used
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to identify PIMs in the elderly are
explicit criteria.1,2 The Beers list was the
first explicit criteria developed for
identifying PIMs in the elderly.
Introduction

Anticipating ADRs is not only aimed at
preventing bothersome side effects but also
decreasing mortality. It has been shown that up
to 44% of fatal, life threatening or serious ADRs
in the nursing home may be preventable.12

Elderly patients are at a higher risk of
developing adverse drug reactions (ADRs)
compared to their younger counterparts.4,5
The most important risk factor for the
occurrence of ADRs in the elderly is the use of
PIMs.6 A recent study found that the use of
PIMS in the elderly was associated with 7.2
billion dollars in healthcare costs in 2001.5 For
every dollar elderly patients spend on
medications, an additional dollar is spent to
manage ADRs with PIMs.7 PIMS are also
associated with impaired physical performance
and increased rate of hospitalizations in elderly
patients living in the community.8,9

Physiologic Changes
There are several obvious physical changes
associated with aging, yet those that cannot be
assessed visually can have an important impact
on drug therapy selection. After age 30, renal
function declines approximately 10% per
decade of life.10 For those living into their 80s,
renal function can be difficult to properly
estimate based on lower lean body mass. The
importance of evaluating risk versus benefit
with medication selection is imperative in older
adults.

Older adults are at an increased risk for ADRs
due to polypharmacy and changes in their
pharmacokinetic and pharmacodynamic
profiles. Currently, patients over the age of 65
comprise approximately 12% of the total
population in the United States. However, they
consume one-third of the prescription and onehalf of the over-the-counter medications.5,10
By the year 2030, this population is expected to
grow to 71 million, or 20% of the total United
States (US) population.11 Elderly patients take
on average five prescriptions and about 50% of
this population experiences polypharmacy.6 As
this subset of the population grows,
pharmacists practicing in community, hospital
and long-term care settings will have increased
opportunities to optimize medication regimens
and prevent ADRs in these at risk patients.

2

Cardiovascular changes in the geriatric
population are important to appreciate when
establishing medication goals and anticipating
adverse effects. Stiffening of the arteries seen
with aging, specifically the aorta, can increase
the likelihood of isolated systolic hypertension.
Lack of response to pressure changes in the
arteries results in decreased vasoconstriction as
compared to a normal baroreceptor reflex seen
in a healthy younger adult population.13 This
change predisposes the elderly to orthostatic
hypotension and consequently, falls.
Ambulation status of patients should be
considered before initiating medications
associated with a high incidence of orthostatic
hypotension.
Sensory changes in the older adult may
complicate medication monitoring. High
frequency sounds such as a woman’s voice are
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the first to be lost with age-related hearing loss.
Cerumen tends to be drier in the elderly
predisposing this population to impaction and
consequently hearing loss. The auditory
changes can be perceived as signs of cognitive
impairment. Older adults may also suffer from
vision changes such as decreased depth
perception and increased time to accommodate
to changes in lighting.14 Vision changes as
described may increase risk of falls, highlighting
the need for environments free of fall or
tripping hazards. Sensory changes associated
with aging and their consequences should be
considered to avoid additive effects with
medication use. Anticholinergic side effects
such as those seen with over the counter
medications like diphenhydramine can lead to
confusion and blurred vision. These side effects
cannot only endanger patients but also present
a challenge when assessing patients for
diagnostic purposes. In addition to vision and
hearing changes, dexterity impairment in the
hands associated with arthritis may make
medication adherence a challenge. Such
patients may benefit from medication
organizers and prescription vials with large,
easy to open lids.
Pharmacokinetics and Pharmacodynamics
Changes in absorption, distribution, metabolism
and elimination (ADME) may predispose elderly
patients to drug toxicities. (Table 1) In most
older adults without a history of gastrointestinal
disease, absorption is the least affected ADME
parameter.4,5,10,15 Decreased gastrointestinal
motility may retard absorption of medications
but overall absorption remains unchanged.
Decreased total body water results in a smaller
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volume of distribution for hydrophilic
medication (e.g.,. lithium and aminoglycosides),
supporting the need for smaller initial doses of
these agents. Lipophilic medications (e.g.,.
diazepam and amiodarone) may accumulate
due to an increase in adipose tissue; therefore,
smaller doses or less frequent dosing may be
preferred.10 First pass metabolism is decreased
in the older adult resulting in an increased
bioavailability of medications such as morphine.
While usage of morphine is not avoided in older
adults, conservative initial dosing addresses any
changes that may occur with normal aging. A
decline in cytochrome P450 activity should be
anticipated when selecting medications in
geriatric patients. However, all medications
undergoing Phase I metabolism may not be
affected based on variability in isoenzyme
groups. A decrease in CYP 2 C19 has been
shown, but consistent changes in CYP 2D6 have
not been found. In addition, these changes
have varied based on overall health status of
the older adults studied. Changes in phase II
metabolism should not be anticipated. As
mentioned previously, elimination is affected by
an age related decline in kidney function.
Lower lean body mass may result in inaccurate
interpretation of serum creatinine. When
estimating creatinine clearance based on
Cockroft Gault, some clinicians round the serum
creatinine to 1 to account for lower lean body
mass in the older adult population. This
practice may underestimate clearance in
healthy, ambulatory older patients16 resulting in
patients receiving lower medication dosages or
not receiving medication at all. (Figures 1 and 2)
Pharmacodynamic differences in the older adult
are not well understood and vary from patient
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to patient. Because of this, medication changes
should be directed by patient response.
Pharmacodynamic changes in the older adult
may decrease effectiveness and increase
toxicity associated with medication use.4,5,15 A
lack or decreased response to beta blockers,
and short and long acting beta-2 agonists may
correlate with decreased affinity at the beta
receptor in the elderly. 15 Morphine use in the
geriatric patient is associated with an increased
analgesic effect without changes in the risk for
lower respiratory depression.15 Lower doses of
warfarin are often needed to achieve
therapeutic International Normalized Ratios
(INRs) in older adults. One study showed that
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the average weekly warfarin dose needed
decreased by 0.4 mg for every year of age
greater than 80.17 While older patients may
require larger doses of furosemide to achieve
the same diuresis as younger patients, they are
prone to the electrolyte changes associated
with loop diuretics.15 Elderly patients are more
likely to experience the adverse effects
associated with anticholinergic medications,
even those with a low anticholinergic burden
(e.g.,. loperamide, cimetidine). More
importantly, the level of impairment due to
anticholinergic side effects is additive when
multiple medications with these properties are
used in combination.

Table 1
Pharmacokinetic
Parameter

Physiological
Parameter

Changes in the Older Adult

Absorption

Gastric acid production

Distribution

Body fat

Least affected; May see lower acid
production in patient with history of
gastrointestinal disease
Increased Vd of lipid soluble drugs
due to increased body fat
Decreased Vd of water soluble drugs
due to decreased total body water
May see higher concentrations of
unbound drug in highly protein
bound drugs specifically in those
patients with poor nutrition or low
body weight
Decreased blood flow and decreased
extraction via first pass metabolism
Anticipate decrease in all phase 1
reactions; Anticipate more of a
decline in CYP2C19 than in CYP2D6
No significant decrease
Decreased; Most affected

Total body water
Serum albumin

Metabolism

Elimination

4

Liver mass and hepatic
blood flow
Phase I reactions

Phase II reactions
Glomerular filtration
rate
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Figure 1: A general approach that should be taken prior to rounding a serum creatinine to estimate a
creatinine clearance.
 Approach renal dosage adjustments in the geriatric patient considering overall health status of each
individual patient.
 Low albumin related to poor nutrition may result in lower serum creatinine values based on lower
creatinine production. This may lead pharmacist to assess patient’s muscle mass and therefore
accuracy of creatinine clearance when using serum creatinine.
 If a patient appears to have a relatively normal muscle mass for their age, the measured serum
creatinine value should be used to calculate the estimated creatinine clearance.
 Alternatively If a patient appears thin, frail or to have low muscle mass, the serum creatinine may be
less reliable when estimating creatinine clearance. In this case, the pharmacist needs to assess the
risk versus the benefit of medication use. The risk of toxicities outside of the therapeutic index of
medication in addition to the acuity of illness should be considered for all therapies. If a decision is
made to round the creatinine to 1.0 when estimating the clearance, consequences of underdosing
should be considered.
Figure2:
Patient Scenario: KL is an 92 yo female residing in Florida. She walks around her senior living community
for 30 minutes each morning with her husband. Her height is 5’2” and her weight is 132 pounds. Her
most recent creatinine was 0.8 mg/dL. Patient has a penicillin allergy and has experienced confusion
when taking quinolone antibiotics in the past. What dosage of sulfamethoxazole/trimethoprim would
you recommend to treat a urinary tract infection in this patient?
 CrCl calculated using 0.8 mg/dL = 36 ml/min
 CrCl calculated rounding to 1.0 mg/dL = 28 ml/min
Dosing Recommendations for Sulfamethoxazole/Trimethoprim:
 CrCl > 30 ml/min: No dosage adjustment needed
 CrCl 15-30 ml/min: Reduce dose by 50%
Literature Review
Beers Criteria
In 1991 a group of geriatric practitioners led by
the late Mark Beers, MD developed consensus
guidelines known as the Beers criteria.3 These
guidelines were originally intended to guide
safe medication use in the sickest elderly
population, nursing home residents. The Beers
criteria were updated in 1997, 2003 and most
recently in 2012. The 2012 updates were
completed in collaboration with the American
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Geriatrics Society (AGS) and this update was
designated for use in all patients over 65 years
of age. The current criteria are graded
according to quality (high, moderate, low) and
strength (strong, weak, insufficient) of
recommendation evidence. The Beers criteria
are intended to improve care in older adults by
reducing risk of exposure to PIMs. The 2012
criteria designate 38 individual medications or
medication classes as PIMS with a
recommendation for avoidance. Fourteen
diseases and PIMs based on drug-disease or
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drug-syndrome interaction are given an
avoidance recommendation. Five medications
or groups of medications with similar
mechanisms of action are designated as use
with caution (Tables 2-5).
The 38 medications or medication classes with a
recommendation for avoidance are organized
by organ system, therapeutic category or drug.
The first category listed highlights the potential
for adverse effects when using medications
with anticholinergic properties. Constipation,
confusion and dry mouth are specifically
addressed as reasons for avoidance with a list
of first-generation antihistamines.
Antispasmodics additionally are highlighted in
the anticholinergic category with a
recommendation for avoidance based on lack of
efficacy. Cardiovascular medications,
specifically alpha1 blockers, central alpha
agonists and nifedipine, are included due their
risk of orthostatic hypotension. The central
nervous system category identifies first and
second generation antipsychotics and their
ability to increase the risk of stroke and
mortality in patients with dementia.
Additionally, short acting (e.g.,. alprazolam,
lorazepam) and long acting (e.g.,. diazepam,
chlordiazepoxide) anxiolytics are given an
avoidance recommendation with falls and
cognitive impairment being listed among other
rationale.
The 14 disease/conditions and PIMS to avoid
include several examples of adverse effects
associated with anticholinergic medication use
in addition to increased medication sensitivity
based on pharmacodynamic changes in the
elderly population. In patients with delirium,
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cognitive impairment, chronic constipation and
benign prostatic hyperplasia, anticholinergics
are given an avoidance recommendation based
on their potential to worsen symptoms
associated with these conditions. Peripheral
alpha blockers and tertiary tricyclic
antidepressants are recommended to be
avoided in patients with syncope based on their
ability to cause orthostatic hypotension.
The five categories of medication designated as
“to be used with caution in older adults” are
associated with an increased risk of adverse
effects or lack of evidence of usefulness in the
elderly population. Aspirin is given a use with
caution recommendation for primary
prevention based of lack of evidence in patients
80 and older. Dabigatran and prasugrel are
included in this section based on a greater risk
of bleeding in older adults. In addition, lack of
safety and efficacy of dabigatran in creatinine
clearance < 30 ml/min is addressed in the
rationale. Antipsychotics and antidepressants
with serotonin receptor activity are included
based on their association with hyponatremia.
Lastly, the vasodilator class is included due to
potential exacerbation of syncope in patients
with a history of syncope. While the cautionary
recommendation regarding antipsychotics and
antidepressants association with hyponatremia
is given a strong strength of recommendation,
all others in this section of Beers are given a
weak strength of recommendation.
STOPP/START
The STOPP/START (Screening Tool of Older
Persons’ Prescriptions /Screening Tool to Alert
doctors to Right Treatment) criteria were
developed by a consensus panel from the
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United Kingdom and Ireland.18 The
STOPP/START lists were created to be used
across Europe for persons age 65 and older.
The goal of the group was to create a tool with
four characteristics: comprehensive and valid
list, based on current clinical evidence, reflect
the consensus opinion of a multi-disciplinary
panel and include drug-drug and drug-disease
interactions. Both lists are organized based on
physiologic system affected by the particular
drugs.
The STOPP list includes sixty-five criteria from
seven physiologic systems. The physiologic
systems included are as follows: cardiovascular,
central nervous system and psychotropic drugs,
gastrointestinal, respiratory, musculoskeletal,
urogenital and endocrine. The list also includes
drugs that adversely affect patients prone to
falls, analgesic drugs and a statement on
duplicate drug classes. Inclusion on the list in
the physiologic systems is primarily due to four
reasons: increased risk for toxicity or disease
exacerbation (Table 2), no evidence or
indication for use (Table 3), safer, more
effective alternatives available (Table 4) and
increased risk for adverse drug reactions (Table
5).
The four most common medications or
medication classes mentioned are aspirin,
tricyclic antidepressants (TCAs), non-steroidal
anti-inflammatory drugs (NSAIDs) and
antimuscarinic drugs. The most common drug
listed in the cardiovascular system subsection is
aspirin. Use of aspirin in the elderly may be
inappropriate in the following situations: in
combination with warfarin; in patients with a
history of peptic ulcer disease; doses > 150
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mg/day; in patients with no history of coronary,
cerebral, or peripheral vascular symptoms; or
treating dizziness not attributed to
cerebrovascular disease. The use of aspirin in
combination with warfarin and peptic ulcer
disease is considered appropriate if given
concomitantly with a histamine H2-receptor
antagonist (H2RA) or proton pump inhibitor
(PPI). Tricyclic antidepressants (e.g.,.
amitriptyline, imipramine, nortriptyline) are the
most common medication class described in the
central nervous system. TCAs are potentially
inappropriate when used in patients with
dementia and glaucoma because of the risk of
worsening cognitive impairment and
exacerbating glaucoma, respectively. TCAs may
cause cardiac conductive abnormalities putting
the patient at risk for arrhythmias and cause
constipation. Non-steroidal anti-inflammatory
drugs (e.g.,. ibuprofen, naproxen, ketoprofen)
are potentially inappropriate in the elderly
because the use may exacerbate moderate to
severe hypertension and heart failure. Also the
long term use in mild osteoarthritis may not be
warranted and other analgesics, such as
acetaminophen, are preferred for maintenance
therapy. The risk of gastrointestinal bleeding
when using an NSAID without the use of a
protective agent (H2RA or PPI) is addressed
within this section. Lastly, the most common
medication class listed in the STOPP criteria is
the antimuscarinic drugs (e.g.,. oxybutynin,
tolterodine) in the urogenital system
subcategory. Antimuscarinics are associated
with increased confusion and agitation in
dementia, exacerbation of glaucoma, chronic
constipation and prostatism.
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The three subcategories of medications not
listed as physiologic systems are drugs that
affect patients with history of falls, analgesic
drugs and duplicate classes. The drugs
identified as those that increase the risk of falls
include benzodiazepines, neuroleptic drugs,
first generation antihistamines, vasodilators and
long term opiates. All of these medications may
cause excessive sedation, reduce sensorium and
impair balance either through gait disturbances
or postural hypotension. The subcategory of
analgesic drugs addresses the use of opiates,
such as fentanyl or morphine, as first line for
mild to moderate pain, and the adverse effect
of constipation with opiate use more than 2
weeks. Lastly, the list includes a statement on
the use of duplicate medications or drug classes
and the recommendation to optimize one
medication prior to addition of another agent.
The START list is one of the first lists that
describe medications that are likely to be
beneficial to the patient that are commonly
omitted. Most lists in the past have been
medications to exclude rather than ones to
include. Similar to the STOPP list, the START list
is organized into six physiologic systems (Table
6). The list includes the consideration of aspirin
and statin therapy for patients with coronary,
cerebral or peripheral vascular disease. Also,
consideration is recommended for angiotensin
converting enzyme inhibitors in patients with
chronic heart failure and acute myocardial
infarction. The list also describes the inhaled
therapies to use in mild to moderate and
moderate to severe chronic obstructive
pulmonary disease. Lastly, the criteria
describes preventative therapy with aspirin and
statin therapy in patients with diabetes mellitus
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and concomitant major cardiovascular risk
factors such as hypertension,
hypercholesterolemia, and smoking.
Comparison of Criteria
The Beers criteria and STOPP/START criteria
were developed based on target patient
populations served by the authors of each
guideline. The most obvious difference
between the criteria is the inclusion of the
potential for errors of omission included within
the START criteria. While Beers has undergone
several revisions since the original criteria were
published, opportunities to address untreated
or under-treated conditions have not been
included.
Appropriate lengths of therapy and drug
combinations with similar side effects are
exclusive to the STOPP criteria. Beta blockers
and verapamil are identified as a combination
associated with risk of symptomatic heart block.
Use of warfarin and aspirin in combination
without an H2RA or a PPI is highlighted as a
potential for increased risk of bleeding. In
addition, appropriate length of therapy of
warfarin for treatment of first, uncomplicated
deep vein thrombosis and pulmonary embolism
is emphasized with appropriate lengths not to
exceed 6 and 12 months, respectively. While
inclusion of these lengths of therapy is
important, the most recent CHEST guidelines
include an even shorter length of therapy for
first provoked deep vein thrombosis, 3
months.19 While the medication combinations
or inappropriate lengths of therapy can
predispose patients to adverse effects, the
general practice recommendations regarding
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lengths of therapy and medication
combinations were developed based on
prescribing trends in Europe. Many of the onesentence recommendation summaries included
within STOPP do not provide specific patient
information that should be taken into
consideration when applying these
recommendations. As an example, a dose of
prednisone 5 mg or greater would warrant
screening and impact fracture risk per National
Osteoporosis Foundation but is not specified in
the START criteria.
The Beers criteria do provide more specific
details within recommendations. Examples of
generic drug entities associated with PIMS are
listed as opposed to providing general drug
classes associated with adverse effects, such as
those included in STOPP. Details regarding
Table 2: Increased risk for disease exacerbation or toxicity
Criteria Inclusion: Beers (B) STOPP (S)
Cardiovascular
Alpha1 blockers and syncope/orthostasis
Aspirin and peptic ulcer disease (PUD)
Calcium channel blockers and chronic constipation
Cilostazol and heart failure
Digoxin > 125 mcg/day
Diltiazem or verapamil and NYHA class III or IV heart failure
Dronedarone and heart failure
Non selective beta blockers and chronic obstructive
pulmonary disease
Pioglitazone or rosiglitazone and heart failure
Thiazide diuretic and gout
Central nervous system and psychotropic drugs
Acetylcholinesterase inhibitors and syncope
Antipsychotics and dementia (stroke)
Benzodiazepines and delirium
Long term neuroleptics and parkinsonisms
SSSRIs and hyponatremia
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those patients at greatest risk of ADRs are listed
to guide the clinician in determining
appropriate therapy selection. As an example,
non-COX, selective NSAIDs are labeled as
increasing risk of gastrointestinal bleeding and
peptic ulcer disease in high risk groups. High
risk groups are further explained as those older
than 75 years old, receiving corticosteroids,
receiving anticoagulants, or receiving
antiplatelet medications. Within this
recommendation, proton pump inhibitors and
misoprostol are included as medications that
reduce but do not eliminate risk. The details
provided in Beers help guide safe medication in
the United States based on specifics included
within clinical practice recommendations used
within the US. This risk stratification is not fully
outlined in STOPP.

Criteria
B
B,S
B,S
B
B,S
B,S
B
S
B
S
B
B
B
S
S

Comments
-STOPP recommends PPI or H2RA
with aspirin use and PUD history.
Beers expands upon STOPP and
recommends avoiding aspirin doses
> 325 mg/day unless other
alternatives are not effective
-STOPP and Beers explain
increased risk of digoxin toxicity with
renal impairment. Beers includes
explanation of lack of benefit of
doses of digoxin > 125 mcg/day in
heart failure.
-Beers specifies tertiary TCA’s
(amitriptyline, clomipramine, imipramine,
doxepin > 6mg/day) only as causing
constipations and syncope. In addition,
the safety of doxepin at doses < 6 mg/day
is noted as being comparable to placebo.
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TCAs and constipation
TCAs and delirium
TCAs and dementia
TCAs and glaucoma
TCAs and syncope
TCAs and urinary retention
Endocrine
Androgens and prostate cancer
Corticosteroids and delirium
Estrogens and breast cancer or venous thromboembolism
Estrogens and urinary incontinence
Gastrointestinal
Anticholinergic antispasmodics and chronic constipation
Diphenoxylate, loperamide or codeine phosphate and
severe infective gastroenteritis
H2RAs and delirium/dementia
Prochlorperazine or metoclopramide and parkinsonism
Musculoskeletal
NSAIDs and chronic renal failure
NSAIDs and Heart failure
NSAIDs and moderate-severe hypertension
NSAIDs and PUD, GI bleeding
Urogenital
Antimuscarinic and chronic constipation
Antimuscarinic and chronic prostatism
Antimuscarinic and glaucoma
Bladder antimuscarinic and dementia

B,S
B
B,S
S
B
B,S
B
B
S
B
B,S
S
B
B,S
B,S
B,S
S
B,S
B,S
S
S
B,S

All other TCA related side effects listed
within Beers encompass the entire class.
- STOPP does not specifically list any
medications within the TCA class.

-Beers specifically states that oral and
transdermal estrogen may aggravate
urinary incontinence, excluding
intravaginal application.
-Anticholinergic antispasmodics drugs
listed in Beers but not in STOPP
-Beers does not specifically address length
of use in evidence supporting cognitive
impairment with H2 receptor antagonists
-In contrast to STOPP criteria, Beers
lists risk factors for GI bleeding with
NSAID’s: age>75 yo, oral/parenteral
corticosteroid use, anticoagulant
use or antiplatelet use. Beers further
explains trends with longer use.
-In contrast to STOPP criteria, Beers
excludes bladder antimuscarinics from the
anticholinergic drugs that should be
avoided with benign prostatic hyperplasia

Table 3: No evidence or indication for use
Criteria Inclusion: Beers (B) STOPP (S)
Cardiovascular
Aspirin without history of coronary, cerebral or peripheral vascular
symptoms
Aspirin to treat dizziness not due to cerebrovascular disease
Dipyridamole as monotherapy for cardiovascular secondary prevention
Loop diuretics and ankle edema not due to clinical heart failure
Warfarin for first uncomplicated DVT for longer than 6 months
Warfarin for first uncomplicated PE for longer than 12 months
Central Nervous system and psychotropic drugs
Ergot mesylates
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Criteria
S
S
B,S
S
S
S
B
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Gastrointestinal
PPI for PUD at full therapeutic doses for > 8 weeks
Urogenital
Alpha blockers for long term urinary catheter

Table 4: Increased risk for adverse drug reactions
Criteria Inclusion: Beers (B) STOPP (S)
Cardiovascular
Aspirin >150 mg/day (bleeding)
Aspirin, clopidogrel, dipyridamole or warfarin with bleeding disorder
(bleeding)
Aspirin and warfarin in combination without H2RA or PPI (bleeding)
BB and verapamil (heart block)
Central alpha agonists (CNS effects)
Dipyridamole, short acting (orthostatic hypotension)
Nifedipine IR (hypotension)
Spironolactone > 25 mg/day (hyperkalemia)
Central Nervous system and psychotropic drugs
Anticholinergics to treat EPS (anticholinergic effects)
Barbiturates (physical dependence)
Long term, long acting BZD
Non-BZD hypnotics
Phenothiazines and persons with epilepsy (seizures)
Prolonged use of first generation antihistamines (anticholinergic effects)
TCA and cardiac conductive abnormalities (pro-arrhythmic)
TCA (sedation, orthostatic hypotension)
TCA and opiate or CCB (constipation)
Gastrointestinal
Diphenoxylate, loperamide or codeine phosphate in diarrhea of unknown
cause (delayed diagnosis, toxic megacolon)
Musculoskeletal
Long term corticosteroids as monotherapy for RA or OA (corticosteroid
systemic side effects)
Pentazocine (CNS effects)
Skeletal muscle relaxants (anticholinergic effects and sedation)
Warfarin and NSAID (bleeding)
Urogenital
Alpha blockers (urinary frequency or worsening incontinence, orthostasis)
Nitrofurantoin (pulmonary toxicity)
Endocrine
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Criteria
S
S
S
S
B
B
B
B
B,S
B
B,S
B
B,S
B,S
B,S
B
S
S

S
B
B
S
B,S
B
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BB and Diabetes (mask hypoglycemic symptoms)
Estrogens without progestin with intact uterus (endometrial cancer)
Sliding scale insulin (hypoglycemia)
Sulfonylureas: Glibenclamide [glyburide] or chlorpropamide
(hypoglycemia)
Urinary antispasmodics (anticholinergic effects)

Table 5: Safer, more effective alternative option
Criteria Inclusion: Beers (B) STOPP (S)
Cardiovascular
Antiarrhythmic drugs (Class Ia, Ic, III)
Disopyramide
Dronedarone
Loop diuretic as first line hypertension monotherapy
Ticlopidine
Respiratory
Systemic corticosteroids in moderate-to-severe COPD
Theophylline as monotherapy in COPD
Musculoskeletal
Long term NSAID for mild OA
Long term NSAID or colchicine for chronic gout
Meperidine
Urogenital
Nitrofurantoin (CrCl <60 ml/min)
Endocrine
Desiccated thyroid
Megestrol
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S
B,S
B
B,S
B

Criteria
B
B
B
S
B
S
S
S
S
B
B
B
B

Table 6: START criteria: should be considered for people ≥ 65 years of age with the following
conditions, where no contraindications exist
Cardiovascular
Warfarin and Atrial Fibrillation
Aspirin and atrial fibrillation with contraindication
to warfarin
Aspirin or clopidogrel and atherosclerotic
Anti-hypertensive therapy and SBP > 160 mmHg
coronary, cerebral or peripheral vascular disease in
patients with sinus rhythm
Statin therapy and coronary, cerebral or peripheral ACEI and chronic heart failure
vascular disease
ACEI and acute MI
BB and chronic stable angina
Respiratory system
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Inhaled B2 agonist or anticholinergic for mild to
moderate COPD
Home O2 with chronic type 1 or 2 respiratory
failure
Central nervous system
L-Dopa and Parkinson’s disease with functional
impairment and resultant disability
Gastrointestinal system
PPI and severe GERD
Musculoskeletal system
DMARD with active moderate-severe RA
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Inhaled corticosteroid for moderate to severe
COPD

Antidepressant and moderate-severe depressive
symptoms lasting 3 months
Fiber supplementation and chronic symptomatic
diverticular disease with constipation
Bisphosphonates and maintenance oral
corticosteroid therapy

Calcium and vitamin D supplement and
osteoporosis
Endocrine system
Metformin and T2DM with or without metabolic
ACEI or ARB and diabetes with nephropathy
syndrome
Antiplatelet and DM with one or more major
Statin therapy and DM with one or more
cardiovascular risk factors*
cardiovascular risk factors*
*Major cardiovascular risk factors: hypertension, hypercholesterolemia, smoking history
Abbreviations used in Tables 1-5: ACEI:
angiotensin converting enzyme inhibitor; ARB:
angiotensin receptor blocker; BB: beta blocker;
BZD: benzodiazepine; CCB: calcium channel
blocker; COPD: chronic obstructive pulmonary
disease; CrCl: creatinine clearance; DM:
diabetes mellitus; DMARD: disease modifying
anti-rheumatic drug; DVT: deep vein
thrombosis; EPS: extrapyramidal symptoms;
GERD: gastro-esophageal reflux disease; GI:
gastrointestinal; H2RA: histamine-2 receptor
antagonist; mcg: microgram; MI: myocardial
infarction; NSAID: non-steroidal antiinflammatory drug; NYHA: New York Heart
Association; O2: oxygen; OA: osteoarthritis; PE:
pulmonary embolism; PPI: proton pump
inhibitor; PUD: peptic ulcer disease; RA:
rheumatoid arthritis; SBP: systolic blood
pressure; SSRI: selective serotonin reuptake
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inhibitor; T2DM: type 2 diabetes mellitus; TCA:
tricyclic antidepressant
Other Tools to Identify PIMs
The Beers and the STOPP/START criteria are the
most commonly used recommendations that
identify PIMs in the elderly. Other lists have
been developed in Canada, France, Australia
and Norway.2 The first criteria after the Beers
list came from Canada and is cited as the
Canadian Criteria.20 This criteria was developed
based on limitations of the Beers criteria that
were identified by the authors. In comparison
to the 1997 Beers criteria, the Canadian Criteria
includes more drug-drug and drug-disease
interactions. This list has not been updated
since its origination in 1997. Based on the initial
criteria from Canada, a group of separate
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authors developed The Improving Prescribing in
the Elderly Tool (IPET) in 2000.21 IPET includes
fourteen specific criteria and only includes drugdisease interactions. The narrow spectrum of
interactions and limited number of criteria
prohibits the global use of the IPET criteria.
France was the first European country to
develop criteria for prescribing for the elderly.
The group of experts that developed the French
Consensus Panel List used the 1997 Beers
criteria, the two Canadian criteria and practice
guidelines from France to develop the thirtyfour item list.22 The list is organized into three
categories: unfavorable benefit to risk ratio,
questionable efficacy, and the combination of
the other two categories. The majority of the
criteria address the use of medications with
anticholinergic properties. One difference from
previous criteria is that the French Consensus
Panel List includes alternative medications to
consider.
The same year that STOPP/START was created,
the Australians were developing a prescribing
tool of their own. The Australian Prescribing
Indicators Tool was developed from combining
the most common problems managed by
general practitioners in Australia with the fifty
most common medications prescribed, not
using a consensus panel like previous lists.23
The Australian Prescribing Indicators Tool was
also one of the first lists to include implicit
criteria. The tool is organized by patient
scenarios with specific footnotes and requires
the physician use the list with an accompanying
contraindication table. The indicators are also
described using the desired outcome instead of
the inappropriate situation. The complicated
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manner in which the scenarios must be
interpreted may be a limiting factor for the
broad use of the tool outside of Australia.
The last explicit list that was created was the
Norwegian General Practice (NORGEP) Criteria
in 2009.24 The thirty-seven criteria are divided
between two groups: drugs or drug dosages
and drug combinations considered potentially
inappropriate. Psychotropic medications are
the most common drug class included in the
NORGEP criteria. The limitation to the use of
this list outside of Norway, is the inclusion of
medications not commonly used outside of the
country and medications not limited to the
elderly population.
Application to Pharmacist and Medication
Therapy Management
The aging population in the United States is
rapidly growing and is expected to almost
double by the year 2030. Pharmacists will have
a greater exposure to this patient population in
any setting. This exposure leads to an increased
opportunity to participate in the care of older
adults. Pharmacists need to be aware of
potential physiologic changes while keeping in
mind that the effect of these changes is not
completely understood. This should direct
pharmacists to use conservative dosing in this
patient population until individual response is
identified. It is imperative that pharmacists
consider the whole patient in addition to the
medication list when evaluating the
appropriateness of specific medications based
on the criteria discussed above. The AGS has
developed a document to guide healthcare
practitioners in caring for the geriatric adult.
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Some of the key points applicable to a
pharmacist have been described in Figure three.
Emphasis is placed on medication risk versus
benefit in addition to patient preference
regarding their overall healthcare.25 The AGS
recommendations serve as a guideline to
promote safe prescribing in the geriatric
patient; however, practitioner evaluation of
quality evidence is required to assure optimal
medication therapy.
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Figure 3: Key Factors to Consider When
Managing a Geriatric Pharmacotherapy
Regimen:
 Specific requests of patient (generic vs.
brand, once daily dosing, liquid vs. tablet)
 Evidence available to support reaching
outcomes tailored to the patient (living
environment, co-morbidities and length of
time to reach outcomes)
 Drug properties and interactions
(anticipated response based on physiologic
and pharmacokinetic changes, interactions
with multiple medications for multiple comorbidities)
 Involve patient in risk versus benefit
discussion of all medication therapy
 Establish follow up, goals of therapy and
educate on the importance of adherence to
follow up

The Pharmacists Education Foundation (PEF) is accredited by the Accreditation council for
Pharmacy Education (ACPE) as a provider of continuing pharmacy education. To receive continuing
pharmacy education (CPE) credit, pharmacists MUST COMPLETE AN ONLINE QUIZ AND EVALUATION
FORM. A score of 70% or above is required to receive CPE credit. The link to the quiz can be accessed
from the MEMBERS page of the IPA website at www.indianapharmacists.org. This is a free service to IPA
members in 2013. Initial release date 12/20/2013. Expiration Date:12/20/2016. Questions: Call IPA at
(317) 634-4968.
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INSTRUCTIONS: This page is intended to help participants REVIEW the quiz prior to submitting
their answers online. Please take the quiz online using the members section of the website.
Geriatric Medication Therapy: Weighing the Evidence versus Best Practice Questions
Which of the following is the most important risk factor for adverse drug reactions in the elderly?
a. Polypharmacy
b. Decreased absorption in the stomach
c. Use of potentially inappropriate medications
d. Stiffening of the arteries
2. All of the following physiologic changes are associated with aging EXCEPT:
a. Increased liver function tests
b. Stiffening of the arteries
c. Declining renal function
d. Decreased depth perception
3. Which of the following pharmacokinetic changes would you expect in older persons taking
diazepam, a lipophilic medication?
a. No changes
b. Increased volume of distribution
c. Decreased maximal concentration
d. Shorter elimination half life
4. In which of the following medications would you expect to see a pharmacodynamic changes in
the elderly?
a. Warfarin
b. Lisinopril
c. Donepezil
d. Aspirin
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5. AG is an 87 year old male who presents to his PCP for his annual visit. His past medical history is
significant for hypertension, diabetes and atrial fibrillation. His current medications include:
lisinopril, carvedilol, dabigatran and metformin. According to the Beer’s Criteria, which of the
following medications could be considered inappropriate?
a. Lisinopril
b. Carvedilol
c. Dabigatran
d. Metformin
6. MD is an 81 year old female who presents to your pharmacy following her annual PCP visit. Her
past medical history is significant for dementia, hypothyroidism and hypertension. Her current
medication profile includes: donepezil, levothyroxine, hydrochlorothiazide and lisinopril. She
presents a prescription to the pharmacy for amitriptyline 25 mg orally at bedtime for
depression. According to the STOPP/START criteria, which of the following is most appropriate?
a. Fill the prescription as it is written
b. Call the prescriber and recommend to increase the dose to 50 mg
c. Call the prescriber and recommend to change to another antidepressant
d. Call the prescriber and recommend to decrease the dose to 12.5 mg
7. JT is a 92 year old male who presents to his cardiologist for a routine check-up. His past cardiac
history is significant for atrial fibrillation, heart failure, and peripheral vascular disease. His
medications include: aspirin 325 mg orally daily, cilostazol 100 mg orally BID, diltiazem 320 mg
ER PO daily and dronedarone 400 mg orally BID. Which of the following medications is deemed
potentially inappropriate by BOTH Beer’s criteria and STOPP/START list?
a. Dronedarone
b. Diltiazem
c. Cilostazol
d. Aspirin
8. Which of the following statements is true regarding the gaps in the Beer’s Criteria as compared
to the STOPP/START list?
a. STOPP/START list includes potential errors of omission
b. The Beer’s list includes duration of therapy
c. The STOPP/START give more specific details within the recommendation
d. The Beer’s list includes drug combinations to be avoided
9. Of the following tools to identify potentially inappropriate medications, which one includes
implicit criteria?
a. Improving Prescribing in the Elderly Tool
b. French Consensus Panel List
c. Norwegian General Practice Criteria
d. Australian Prescribing Indicators Tool
10. When taking care of geriatric patients, pharmacists can do which of the following?
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a. Recommend therapy strictly based on tools used to identify potentially inappropriate
medications
b. Use conservative dosing and titrate based on patient response
c. Make no changes to their recommendations—there are no differences between older
and younger adults
Recommend all changes based on generalized pharmacodynamic and pharmacokinetic changes
in the elderly
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